Anxiety Disorders - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 289 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anxiety Disorders - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Anxiety Disorders - Pipeline Review, H2 2015', provides an overview of the Anxiety Disorders's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anxiety Disorders, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anxiety Disorders and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anxiety Disorders
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anxiety Disorders and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anxiety Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anxiety Disorders pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anxiety Disorders
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anxiety Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Anxiety Disorders Overview 11
Therapeutics Development 12
Pipeline Products for Anxiety Disorders - Overview 12
Pipeline Products for Anxiety Disorders - Comparative Analysis 13
Anxiety Disorders - Therapeutics under Development by Companies 14
Anxiety Disorders - Therapeutics under Investigation by Universities/Institutes 19
Anxiety Disorders - Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Unknown Stage Products 23
Anxiety Disorders - Products under Development by Companies 24
Anxiety Disorders - Products under Investigation by Universities/Institutes 30
Anxiety Disorders - Companies Involved in Therapeutics Development 32
AbbVie Inc. 32
Ache Laboratorios Farmaceuticos S/A 33
Adamed Sp. z o.o. 34
Addex Therapeutics Ltd 35
Avineuro Pharmaceuticals, Inc. 36
Azevan Pharmaceuticals, Inc. 37
Bionomics Limited 38
Boehringer Ingelheim GmbH 39
C4X Discovery Limited 40
Catalyst Pharmaceutical Partners, Inc. 41
Edgemont Pharmaceuticals, LLC 42
Eisai Co., Ltd. 43
Eli Lilly and Company 44
F. Hoffmann-La Roche Ltd. 45
Gabather AB 46
GW Pharmaceuticals Plc 47
H. Lundbeck A/S 48
HolsboerMaschmeyer NeuroChemie GmbH 49
Humanetics Corporation 50
Intra-Cellular Therapies, Inc. 51
Johnson & Johnson 52
Marinus Pharmaceuticals, Inc. 53
Merz Pharma GmbH & Co. KgaA 54
MI.TO. Technology S.r.L. 55
Neuralstem, Inc. 56
Neurocrine Biosciences, Inc. 57
NeuroNascent, Inc. 58
Newron Pharmaceuticals S.p.A. 59
Nippon Chemiphar Co., Ltd. 60
Novartis AG 61
Omeros Corporation 62
Otsuka Holdings Co., Ltd. 63
Pherin Pharmaceuticals, Inc. 64
Polleo Pharma Limited 65
Protagenic Therapeutics Inc. 66
Rottapharm SpA 67
Sellas Inc. 68
Suda Ltd 69
Sumitomo Dainippon Pharma Co., Ltd. 70
Synchroneuron Inc. 71
Tonix Pharmaceuticals Holding Corp. 72
Trevena, Inc. 73
Vanda Pharmaceuticals Inc. 74
Anxiety Disorders - Therapeutics Assessment 75
Assessment by Monotherapy Products 75
Assessment by Target 76
Assessment by Mechanism of Action 80
Assessment by Route of Administration 84
Assessment by Molecule Type 86
Drug Profiles 88
18-MC - Drug Profile 88
acamprosate calcium SR - Drug Profile 89
ACH-36 - Drug Profile 91
ADN-2013 - Drug Profile 92
ADX-71441 - Drug Profile 93
ADX-71743 - Drug Profile 94
ADX-88178 - Drug Profile 95
alprazolam - Drug Profile 96
AM-3506 - Drug Profile 97
AVN-101 - Drug Profile 98
AVN-628 - Drug Profile 99
BCA-909 - Drug Profile 100
BHV-0223 - Drug Profile 101
BNC-210 - Drug Profile 103
brexpiprazole - Drug Profile 105
CPP-115 - Drug Profile 108
CR-5542 Series - Drug Profile 110
dipraglurant IR - Drug Profile 111
Drug for Post-Traumatic Stress Disorders - Drug Profile 112
Drugs to Inhibit FAAH for CNS Disorders - Drug Profile 113
Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile 114
Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile 115
E-2508 - Drug Profile 116
evenamide - Drug Profile 117
fluvoxamine maleate - Drug Profile 118
Gaaba-001 - Drug Profile 119
ganaxolone - Drug Profile 120
HL-9001 - Drug Profile 122
IC-87201 - Drug Profile 123
iloperidone - Drug Profile 124
ITI-007 - Drug Profile 126
JNJ-42165279 - Drug Profile 128
lorazepam ER - Drug Profile 129
LSN-2535717 - Drug Profile 130
LY-2607540 - Drug Profile 131
mavoglurant - Drug Profile 132
midazolam hydrochloride - Drug Profile 134
MRZ-8676 - Drug Profile 135
nabiximols - Drug Profile 136
NB-51R1 - Drug Profile 139
NEO-1940 - Drug Profile 140
NNI-351 - Drug Profile 141
NSI-189 - Drug Profile 142
OMS-527 - Drug Profile 144
Peptide to Activate NPSR for Sleep Disorders and Anxiety Disorders - Drug Profile 145
PH-94B - Drug Profile 146
PT-00114 - Drug Profile 148
PT-00121 - Drug Profile 149
PT-00211 - Drug Profile 150
PT-00411 - Drug Profile 151
RO-646198 - Drug Profile 152
Rycal - Drug Profile 153
S-107 - Drug Profile 154
SCT-66 - Drug Profile 155
Small Molecule to Antagonize CRF-1 Receptor for Anxiety Disorders - Drug Profile 156
Small Molecule to Antagonize GPR31 for Anxiety Disorders - Drug Profile 157
Small Molecule to Target GPR151 for CNS Diseases - Drug Profile 158
Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis - Drug Profile 159
Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile 160
Small Molecule to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile 161
Small Molecules for Autism Spectrum Disorders and Obsessive Compulsive Disorders - Drug Profile 162
Small Molecules for Post-Traumatic Stress Disorder - Drug Profile 163
Small Molecules to Activate Sigma Receptor for Panic and Schizoaffective Disorders - Drug Profile 164
Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile 165
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 166
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 168
Small Molecules to Agonize D2 and Inhibit MAO for Depression and Anxiety - Drug Profile 169
Small Molecules to Agonize Delta Opioid Receptor for Anxiety and Depression - Drug Profile 170
Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 171
Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile 172
Small Molecules to Antagonize mGluR3 for Anxiety and Depression - Drug Profile 173
Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile 174
Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile 175
Small Molecules to Antagonize Orexin-1 Receptor for CNS Disorders - Drug Profile 176
Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 177
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 178
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 179
Small Molecules to Modulate Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile 180
Small Molecules to Target Nicotinic Acetylcholine Receptors for Anxiety Disorder - Drug Profile 181
SRX-246 - Drug Profile 182
STX - Drug Profile 184
tedatioxetine hydrobromide - Drug Profile 185
TNX-102 - Drug Profile 187
TPI-136117 - Drug Profile 189
TRV-250 - Drug Profile 190
UCM-765 - Drug Profile 192
Vaccine for CNS Disorders - Drug Profile 193
VAD-1 - Drug Profile 194
VAD-2 - Drug Profile 195
verucerfont - Drug Profile 196
vigabatrin - Drug Profile 198
vortioxetine hydrobromide - Drug Profile 201
VU-0431316 - Drug Profile 204
ZL-006 - Drug Profile 205
zolpidem tartrate - Drug Profile 206
Anxiety Disorders - Recent Pipeline Updates 207
Anxiety Disorders - Dormant Projects 256
Anxiety Disorders - Discontinued Products 270
Anxiety Disorders - Product Development Milestones 275
Featured News & Press Releases 275
Appendix 282
Methodology 282
Coverage 282
Secondary Research 282
Primary Research 282
Expert Panel Validation 282
Contact Us 282
Disclaimer 283

List of Tables

Number of Products under Development for Anxiety Disorders, H2 2015 18
Number of Products under Development for Anxiety Disorders - Comparative Analysis, H2 2015 19
Number of Products under Development by Companies, H2 2015 21
Number of Products under Development by Companies, H2 2015 (Contd..1) 22
Number of Products under Development by Companies, H2 2015 (Contd..2) 23
Number of Products under Development by Companies, H2 2015 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2015 25
Comparative Analysis by Late Stage Development, H2 2015 26
Comparative Analysis by Clinical Stage Development, H2 2015 27
Comparative Analysis by Early Stage Development, H2 2015 28
Comparative Analysis by Unknown Stage Development, H2 2015 29
Products under Development by Companies, H2 2015 30
Products under Development by Companies, H2 2015 (Contd..1) 31
Products under Development by Companies, H2 2015 (Contd..2) 32
Products under Development by Companies, H2 2015 (Contd..3) 33
Products under Development by Companies, H2 2015 (Contd..4) 34
Products under Development by Companies, H2 2015 (Contd..5) 35
Products under Investigation by Universities/Institutes, H2 2015 36
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 37
Anxiety Disorders - Pipeline by AbbVie Inc., H2 2015 38
Anxiety Disorders - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 39
Anxiety Disorders - Pipeline by Adamed Sp. z o.o., H2 2015 40
Anxiety Disorders - Pipeline by Addex Therapeutics Ltd, H2 2015 41
Anxiety Disorders - Pipeline by Avineuro Pharmaceuticals, Inc., H2 2015 42
Anxiety Disorders - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015 43
Anxiety Disorders - Pipeline by Bionomics Limited, H2 2015 44
Anxiety Disorders - Pipeline by Boehringer Ingelheim GmbH, H2 2015 45
Anxiety Disorders - Pipeline by C4X Discovery Limited, H2 2015 46
Anxiety Disorders - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015 47
Anxiety Disorders - Pipeline by Edgemont Pharmaceuticals, LLC, H2 2015 48
Anxiety Disorders - Pipeline by Eisai Co., Ltd., H2 2015 49
Anxiety Disorders - Pipeline by Eli Lilly and Company, H2 2015 50
Anxiety Disorders - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 51
Anxiety Disorders - Pipeline by Gabather AB, H2 2015 52
Anxiety Disorders - Pipeline by GW Pharmaceuticals Plc, H2 2015 53
Anxiety Disorders - Pipeline by H. Lundbeck A/S, H2 2015 54
Anxiety Disorders - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2015 55
Anxiety Disorders - Pipeline by Humanetics Corporation, H2 2015 56
Anxiety Disorders - Pipeline by Intra-Cellular Therapies, Inc., H2 2015 57
Anxiety Disorders - Pipeline by Johnson & Johnson, H2 2015 58
Anxiety Disorders - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015 59
Anxiety Disorders - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015 60
Anxiety Disorders - Pipeline by MI.TO. Technology S.r.L., H2 2015 61
Anxiety Disorders - Pipeline by Neuralstem, Inc., H2 2015 62
Anxiety Disorders - Pipeline by Neurocrine Biosciences, Inc., H2 2015 63
Anxiety Disorders - Pipeline by NeuroNascent, Inc., H2 2015 64
Anxiety Disorders - Pipeline by Newron Pharmaceuticals S.p.A., H2 2015 65
Anxiety Disorders - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015 66
Anxiety Disorders - Pipeline by Novartis AG, H2 2015 67
Anxiety Disorders - Pipeline by Omeros Corporation, H2 2015 68
Anxiety Disorders - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 69
Anxiety Disorders - Pipeline by Pherin Pharmaceuticals, Inc., H2 2015 70
Anxiety Disorders - Pipeline by Polleo Pharma Limited, H2 2015 71
Anxiety Disorders - Pipeline by Protagenic Therapeutics Inc., H2 2015 72
Anxiety Disorders - Pipeline by Rottapharm SpA, H2 2015 73
Anxiety Disorders - Pipeline by Sellas Inc., H2 2015 74
Anxiety Disorders - Pipeline by Suda Ltd, H2 2015 75
Anxiety Disorders - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 76
Anxiety Disorders - Pipeline by Synchroneuron Inc., H2 2015 77
Anxiety Disorders - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015 78
Anxiety Disorders - Pipeline by Trevena, Inc., H2 2015 79
Anxiety Disorders - Pipeline by Vanda Pharmaceuticals Inc., H2 2015 80
Assessment by Monotherapy Products, H2 2015 81
Number of Products by Stage and Target, H2 2015 83
Number of Products by Stage and Mechanism of Action, H2 2015 87
Number of Products by Stage and Route of Administration, H2 2015 91
Number of Products by Stage and Molecule Type, H2 2015 93
Anxiety Disorders Therapeutics - Recent Pipeline Updates, H2 2015 213
Anxiety Disorders - Dormant Projects, H2 2015 262
Anxiety Disorders - Dormant Projects (Contd..1), H2 2015 263
Anxiety Disorders - Dormant Projects (Contd..2), H2 2015 264
Anxiety Disorders - Dormant Projects (Contd..3), H2 2015 265
Anxiety Disorders - Dormant Projects (Contd..4), H2 2015 266
Anxiety Disorders - Dormant Projects (Contd..5), H2 2015 267
Anxiety Disorders - Dormant Projects (Contd..6), H2 2015 268
Anxiety Disorders - Dormant Projects (Contd..7), H2 2015 269
Anxiety Disorders - Dormant Projects (Contd..8), H2 2015 270
Anxiety Disorders - Dormant Projects (Contd..9), H2 2015 271
Anxiety Disorders - Dormant Projects (Contd..10), H2 2015 272
Anxiety Disorders - Dormant Projects (Contd..11), H2 2015 273
Anxiety Disorders - Dormant Projects (Contd..12), H2 2015 274
Anxiety Disorders - Dormant Projects (Contd..13), H2 2015 275
Anxiety Disorders - Discontinued Products, H2 2015 276
Anxiety Disorders - Discontinued Products (Contd..1), H2 2015 277
Anxiety Disorders - Discontinued Products (Contd..2), H2 2015 278
Anxiety Disorders - Discontinued Products (Contd..3), H2 2015 279
Anxiety Disorders - Discontinued Products (Contd..4), H2 2015 280